NeuroMetrix Launches www.DPNCheck.com To Support Growing NC-stat DPNCheck Business

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq:NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced the launch of www.DPNCheck.com. The website is an important online resource that will help support the growing domestic and international DPNCheck^® business. DPNCheck is a fast, accurate and quantitative point-of-care test for diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet medical need for better and more cost-effective screening, diagnosing and monitoring of DPN. This complication affects over 50% of people with diabetes and leads to foot ulcers and limb amputation, as well as severe pain and an overall reduction in patient quality of life.

www.DPNCheck.com contains content to help healthcare providers, managed care organizations, and other stakeholders understand DPN and the clinical benefits of early detection and management with DPNCheck. The resources available on the site include monographs, references to scientific studies, and video instruction for DPNCheck testing and interpretation of results.

"We are pleased with the growing acceptance of DPNCheck among Medicare Advantage plans where the test is used in the clinically and financially important risk adjustment process," said Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. "We believe that a branded DPNCheck website will help our efforts to grow this business. We are also gearing up for a launch of DPNCheck into the Japanese market where we are partnering with Omron Healthcare. The website will support Omron's efforts as well as those of our other international partners. We believe that DPNCheck represents an attractive high-margin business opportunity that complements SENSUS and our other therapeutic initiatives."

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.

NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media